Price
65
+5.26%52W Range
Market Cap
₹32.76 Cr
Traded: ₹0.00 Cr (0.00%) 0.0x
Free Float: ₹7.17 Cr (0.00% of FF traded)
Volume · 60D trend
10 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | -2.0% | -2.0% | -5.0% | -- | -- | Stable |
| Sales | +13.0% | +21.0% | +25.0% | -- | +37.0% | Accelerating |
| Profit | +11.0% | +80.0% | +145.0% | -- | +127.0% | Stable |
| Return | -1.0% | -2.0% | -13.0% | -17.0% | -- | Decelerating |
Quarterly Results
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023PDF ↗ | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 30 | 57 | 30 | 32 | 31 | 26 | 26 | 26 | 22 | 24 | 20 | 22 | 20 |
| Expenses | 27 | 55 | 27 | 32 | 34 | 27 | 26 | 25 | 22 | 25 | 21 | 21 | 20 |
| Operating Profit | 3 | 2 | 3 | 1 | -3 | -1 | -0 | 1 | 0 | -1 | -0 | 1 | -0 |
| OPM % | 10.3% | 2.9% | 10.0% | 2.5% | -9.2% | -3.6% | -0.2% | 4.0% | 0.0% | -2.6% | -1.4% | 6.1% | -1.9% |
| Other Income | -1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
| Profit Before Tax | 1 | 1 | 2 | -1 | -4 | -2 | -1 | 0 | -1 | -1 | -1 | 1 | -2 |
| Tax % | -3.7% | -4.4% | 3.7% | 14.3% | 4.8% | 2.7% | 5.5% | 600.0% | 30.4% | 0.0% | 0.0% | 0.0% | -5.0% |
| Net Profit | 1 | 1 | 2 | -1 | -4 | -2 | -1 | 0 | -1 | -1 | -1 | 1 | -2 |
| Exceptional Items | -1 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Rs) | 0.4 | 0.9 | 3.2 | -2.0 | -7.0 | -4.0 | -2.4 | -0.5 | -1.8 | -2.5 | -2.3 | 1.0 | -3.8 |
| Sales Growth (YoY) | -4.0% | 120.1% | 15.4% | 24.2% | 43.9% | 7.3% | 28.1% | 16.9% | 8.0% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -47.5% | 88.2% | -6.6% | 4.2% | 20.2% | -1.3% | 0.5% | 20.7% | -10.3% | 17.8% | -8.4% | 11.5% | -- |
| OP Growth (YoY) | 207.7% | 276.6% | 5133.3% | -23.1% | -- | -51.6% | 79.3% | -23.0% | 100.0% | -- | -- | -- | -- |
| OP Growth (QoQ) | 85.5% | -45.0% | 277.5% | 128.0% | -204.3% | -1466.7% | -105.8% | -- | 100.0% | -113.8% | -121.5% | 446.2% | -- |
| Profit Growth (YoY) | 112.0% | 130.0% | 231.0% | -308.0% | -290.0% | -62.0% | -4.0% | -148.0% | 53.0% | -21.0% | -238.0% | -73.0% | -395.0% |
| EPS Growth (YoY) | 105.4% | 121.6% | 231.0% | -304.0% | -288.9% | -62.5% | -4.3% | -148.5% | 52.5% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -56.3% | -72.6% | 256.9% | 71.3% | -74.7% | -66.5% | -384.0% | 72.4% | 27.0% | -6.9% | -325.2% | 127.0% | -- |
| OP Margin | 10.3% | 2.9% | 10.0% | 2.5% | -9.2% | -3.6% | -0.2% | 4.0% | 0.0% | -2.6% | -1.4% | 6.1% | -1.9% |
| Net Margin | 3.8% | 1.2% | 6.1% | -2.0% | -13.3% | -7.4% | -4.4% | 0.4% | -4.1% | -6.0% | -5.8% | 2.4% | -10.4% |
| Material Cost % | 66.0% | 80.0% | 61.0% | 68.0% | 73.0% | 63.0% | 66.0% | 66.0% | 67.0% | 73.0% | 65.0% | 66.0% | 70.0% |
| Employee Cost % | 11.0% | 6.0% | 14.0% | 15.0% | 15.0% | 17.0% | 17.0% | 16.0% | 17.0% | 15.0% | 16.0% | 13.0% | 14.0% |
| P/S | 0.22 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 27.08 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 0.62 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Please find attached copies of newspaper cuttings of the extract of Statement of unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026, published in ....
Enclosed please find the unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. The above unaudited Financial Results and the Limited Review Reports ....
The meeting of the Board of Directors of the Company was held on August 12, 2026 which considered and took on record inter alia the unaudited Standalone and Consolidated Financial Results ....
Pursuant to Regulation 34 (1) (a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed please find a copy of the Annual Report along with the Notice of ....
Pursuant to Regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Section 91 of the Companies Act 2013, read with Rule 10 of Companies (Management ....
GKB Ophthalmics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve the Standalone and Consolidated ....
In continuation to intimation filed by the company on September 12, 2025 informing of the development in relation to the ongoing Litigation wherein an Award was passed by the Industrial ....
Please find herewith Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018, for the quarter ended June 30, 2026. Kindly acknowledge the receipt of the same.
Pursuant to provision of Regulation 7(2) read with Regulation 6(2) of SEBI ( Prohibition of Insider TRading ) Regulations, 2015 (PIT Regulation 2015) intimation be and is hereby given that ....
Pursuant to SEBI (Prohibition of Insider Trading ) Regulations 2015, as amended from time to time, The "Trading Window" for dealing /Trading in the shares of the Company shall remain closed ....
Please find enclosed copies of newspaper cuttings of the extract of statement of audited Standalone and Consolidated Financial Results for the year ended March 31, 2026, published in Free ....
Enclosed please find the Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026. Kindly take the information on record.
The meeting of the Board of Directors of the Company was held on May 27, 2026 which approved and took on record the Audited Standalone and Consolidated Financial Results of the Company ....
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that CRISIL Ratings Limited (" CRISIL Ratings") has migrated the ....
Pursuant to Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, enclosed please find the Annual Secretarial Compliance Report for the year ended March ....
GKB Ophthalmics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2026 ,inter alia, to consider and approve the Audited Standalone and ....
Pursuant to Circular no. SEBI/HO/DDHS/CIR/P/2018/144, dated November 26,2018, issued by the securities and Exchange Board of India , we hereby confirm that GKB Ophthalmics Limited, is not ....
Please find herewith Certificate under Regulation 74 (5) of SEBI (Depositories and Participants) Regulations , 2018, for the quarter ended March 31, 2026. Kindly acknowledge receipt of the same.
Please find enclosed herewith the disclosure under Regulation 31 (4) of Securities and Exchange Board of India ( Substantial Acquisition of Shares and Takeover ) Regulation 2011 for the ....
Pursuant to SEBI (Prohibition of Insider Trading) Regulation 2015, as amended from time to time , the " Trading Window" for dealing / trading in the shares of the Company shall remain closed ....
A Seperate meeting of Independent Directors'' Meeting of the Company for the year 2025-26, was held, pursuant to Regulation 25(3) of SEBI (Listing Obligations and Disclosures Requirements) ....
Notice is hereby given that pursuant to Regulation 25 (3 & 4) of SEBI (Listing Obligations and Disclosures Requirements) Regulation, 2015, and Schedule IV, clause VII of the Companies Act, ....
Please find enclosed copies of newspaper cuttings of the extract of Statement of Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, ....
The Meeting of the Board of Directors of the Company was held on February 12, 2026, which considered and took on record the Unaudited Standalone and Consolidated Financial Results of the ....
Enclosed please find Unaudited Standalone and Consolidated Financial Results for the Quarter and nine months ended December 31, 2025
GKB Ophthalmics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2026 ,inter alia, to consider and approve the unaudited Standalone and ....
We would like to inform you that the Statutory Auditor''s of the Company, MSKA & Associates, Chartered Accountants have intimated the Company that the Firm has converted itself into a Limited ....
Please find herewith Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018 ,for the quarter ended December 31, 2025. Kindly acknowledge receipt of the same.
Pursuant to provision of Regulation 7(2) read with Regulation 6(2) of SEBI(Prohibition of Insider Trading) Regulations, 2015 (PIT Regulations, 2015), intimation be and is hereby given ....
Pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015, as amended from time to time, the "Trading Window" for dealing/trading in the shares of the Company shall remain closed ....
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, enclosed please find the minutes of Postal Ballot of the Company. Kindly take the ....
Pursuant to Regulation 30 , of SEBI(LODR) Regulation, 2015, we wish to inform you that the members of GSV Ophthalmics Private Limited of Material Subsidiary of the company at their Extraordinary ....
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, we wish to inform you that the Board of Directors of our material subsidiary, GSV Ophthalmics ....
Please find enclosed copies of newspaper cuttings of the extract of Statement of Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, ....
The meeting of the Board of Directors of the Company was held on November 14, 2025, which inter alia considered and took on record the unaudited standalone and consolidated financial results ....
Enclosed please find the unaudited Standalone and Consolidated financial results for the quarter and half year ended September 30, 2025.
This is with reference to our later dated September 30,2025 Wherein the Company had sought the Consent of its member through Postal Ballot by remote evoting vide Postal Ballot Notice dated ....
Pursuant to Section 110 of the Companies Act, 2013 read with Rule 22 of Companies (Management and Administration) Rules, 2014 and Regulation 44 of SEBI (Listing Obligations and Disclosure ....
GKB Ophthalmics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 ,inter alia, to consider and approve the Unaudited Standalone and ....
In Compliance with Regulation 30 read with Schedule III Part A Para B of SEBI ( Listing Obligations and Disclosure Requirements) Regulation ,2015, corporate announcement is hereby given ....
Please find herewith Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30,2025. Kindly acknowledge receipt of the same.
Please find enclosed the newspaper advertisements published in The Times of India, Goa Edition dated October 01,2025 and Pudhari (Marathi Edition) dated October 01, 2025 in connection with ....
Pursuant to Regulation 30, enclosed please find the Postal Ballot Notice dated September 22, 2025, for seeking the approval of the members by way of Ordinary and Special Resolutions, respectively ....
Pursuant to SEBI (Prohibition of Insider Trading ) Regulations 2015, as amended from time to time, the "Trading Window" for dealing/trading in the shares of the Company shall remain close ....
Pursuant to Regulation of SEBI ( Listing Obligations and Disclosure Requirements) Regulations, 2025, we wish to inform that : 1. Intimation from Material Subsidiary proposing to initiate ....
Pursuant to SEBI (Prohibition of Insider Trading) Regulations 2015, as amended from time to time, as the designated persons are reasonably expected to be in possession of unpublished price ....
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to enclosed herewith a copy of the Minutes of the proceedings of the ....
Pursuant to Regulation 30 of SEBI( Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company has received an Order on September 12, 2025 ....
Pursuant to Regulation 44 of SEBI ( Listing Obligations and Disclosure Requirements) Regulations 2015,please find enclosed the following: 1. Consolidated Voting results pursuant to Regulation ....
The 43rd Annual General Meeting of the Company was held at the Registered Office of the Company on Thursday, August 21, 2025, at 11:00 A.M, through Video Conference/ Other Audio Visual ....